Site Editor
Soo Park, MD
Soo Park, MD
Posted: Monday, March 25, 2024
Sophia McKinley, MD, EdM, of Massachusetts General Hospital, Boston, and colleagues conducted a multicenter study to describe patterns of recurrence, subsequent management, and outcomes of high-risk patients with resected cutaneous melanoma who experienced a relapse during or after adjuvant immunotherapy. Their findings, which were presented during the 2024 Society of Surgical Oncology (SSO) Annual Meeting (Abstract 60), may inform the design of future clinical trials.
“Melanoma recurrence following adjuvant immunotherapy was associated with survival similar to the front-line metastatic setting,” the investigators commented. “Site of recurrence, but not whether recurrence occurred during vs after adjuvant immunotherapy, was associated with overall survival.”
The investigators retrospectively identified 250 patients whose disease recurred during or after the completion of adjuvant immunotherapy. Of this population, 97% had stage III disease, and 84% received adjuvant anti–PD-1 therapy. The median duration of time to recurrence was 9.4 months after initial surgical resection. A total of 55% of patients experienced recurrence while undergoing adjuvant therapy.
The median duration of overall survival from the time of first recurrence was 5.2 years. The 3-year rate of overall survival after first recurrence was 61%. Across the study population, 47% of patients underwent curative-intent surgical resection, and 84% received further systemic therapy for their initial recurrence. A significant relationship was observed between the site of first recurrence and overall survival (log-rank P = .035; estimated 3-year rates, local/intransit: 73%; nodal and local/intransit: 76%; nodal: 45%; systemic: 56%). Based on a univariate analysis, first recurrence during adjuvant therapy vs after its discontinuation was not associated with overall survival (log-rank P = .5).
Disclosure: Dr. McKinley reported no conflicts of interest. For full disclosures of the other study authors, visit sso2024.eventscribe.net.
JNCCN Spotlights
Resources
For your Patients
